NEW HAVEN, Conn.–(BUSINESS WIRE) June 19, 2018 –Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of ALXN1210, the…Original Article
Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
